SCHEMBL2094472

SCHEMBL2094472

[CH2]CCOC(=O)N(c1ccccc1)c1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGIR P43119 14/20 0.53
PTGDR Q13258 6/20 0.53
PTGER1 P34995 1/20 0.53
PTGER4 P35408 1/20 0.53
PTGER3 P43115 1/20 0.53
PTGER2 P43116 1/20 0.53
ATM Q13315 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CHRNB2 P17787 1/20 0.42
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
CHRNA4 P43681 1/20 0.42
NPSR1 Q6W5P4 2/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2092271 0.84 PTGIR (0.40) PTGIRPTGDRPTGER1PTGER4PTGER3
SCHEMBL2094901 0.83 PTGIR (0.57) PTGIRPTGDRPTGER4PTGER3PTGER2
SCHEMBL2098556 0.81 PTGIR (0.42) PTGIRPTGDRPTGER1PTGER4PTGER3
SCHEMBL16964891 0.80 TDP1 (0.59) PTGIRPTGDRPTGER1PTGER4PTGER3
SCHEMBL2091077 0.80 TDP1 (0.47) PTGIRPTGDRPTGER1PTGER4PTGER3
SCHEMBL2090682 0.78 PTGIR (0.56) PTGIRPTGDRPTGER4PTGER3PTGER2
SCHEMBL16965819 0.77 TDP1 (0.55) PTGIRPTGDRPTGER1PTGER4PTGER3
SCHEMBL2089370 0.77 PTGIR (0.51) PTGIRPTGDRPTGER1PTGER4PTGER3
SCHEMBL21500508 0.76 L3MBTL1 (0.50) PTGIRPTGDRPTGER1PTGER4PTGER3
SCHEMBL2095968 0.74 TDP1 (0.40) PTGIRPTGDRPTGER1PTGER4PTGER3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 PTGIR 1605/4885PTGDR 427/4885PTGER1 1469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.